Epivax, Inc.: News

News

Dr. Annie De Groot, CEO, awarded YWCA 2008 Women of Achievement Award – September 2008

Awarded $35K Montel Williams Foundation grant for multiple sclerosis research – September 2008

Awarded $600K NIH grant to further research in Type I Diabetes – September 2008

EpiVax Presents Tolerance-inducing "Tregitopes" at Keystone Conference – January 2008

Awarded $350K grant from the Juvenile Diabetes Research Foundation to develop immunomodulatory treatment for type 1 diabetes – October 2007

Awarded $600K NIH grant to Optimize a Multivalent Tuberculosis Vaccine – September 2007

Awarded $350K NIH grant to develop De-immunized Factor FVIII for Hemophelia – July 2007

Awarded $350K NIH grant to develop De-immunized Botulinum Neurotoxin Type A for Dystonia – March 2007

Awarded $990K Smallpox Vaccine Grant – June 2005

Awarded $600K H. Pylori Vaccine Grant – June 2005

EpiVax moves to new facility at 146 Clifford Street including office and laboratory space – November 2004

Awarded $859K Tularemia Vaccine Grant – September 2004

EpiVax signs Master Services Agreement with Amgen – July 2004

EpiVax renews technology license with Brown University – August 2003

EpiVax receives $150,000 in phase II funding from Slater Center for Bio-Technology – March 2003

EpiVax signs Master Services Agreement with Brown University – March 2003

EpiVax signs Laboratory Services Agreement with Eli Lilly – March 2002

Awarded SBIR Phase I grant for West Nile Virus diagnostic project – September 2001

Awarded SBIR Phase I grant for Human Papiloma Virus vaccine project – September 2001

Signed strategic cooperation and co-marketing agreement with Beckman Coulter Immunomics – June 2001

Anne De Groot named Core Scientist by Sequella Global TB Foundation and awarded 3 year $900,000 TB vaccine development grant – April 2000

Awarded SBIR Phase I for HIV vaccine development. Full time operations begin. – September 1999

Awarded phase 1 development grant from Rhode Island’s Slater Center for Biomedical Technology – June 1998

EpiVax, Inc. founded by Dr. Anne De Groot – May 1998

September 2008

Dr. Annie De Groot, CEO, awarded YWCA 2008 Women of Achievement Award

Awarded $35K Montel Williams Foundation grant for multiple sclerosis research

http://www.beloblog.com/ProJo_Blogs/bizblog/2008/09/providencebased-1.html

Awarded $600K NIH grant to further research in Type I Diabetes

http://www.newsrx.com/pr_details.php?type=1&id=5362

January 2008

EpiVax Presents Tolerance-inducing "Tregitopes" at Keystone Conference

October 2007

Awarded $350K grant from the Juvenile Diabetes Research Foundation to develop immunomodulatory treatment for type 1 diabetes

September 2007

Awarded $600K NIH grant to Optimize a Multivalent Tuberculosis Vaccine

July 2007

Awarded $350K NIH grant to develop De-immunized Factor FVIII for Hemophelia

March 2007

Awarded $350K NIH grant to develop De-immunized Botulinum Neurotoxin Type A for Dystonia

June 2005

Awarded $990K Smallpox Vaccine Grant

EpiVax was awarded its second federal biodefence grant for $993,771 to develop a genome-derived, epitope-driven smallpox vaccine. Smallpox, a deadly disease that was eradicated in its natural form decades ago, is still a potential bioterror weapon and a Homeland Security priority.

Awarded $600K H. Pylori Vaccine Grant

EpiVax was awarded a $600,000 Phase I Small Business Innovation Research (SBIR) grant by the NIH. The grant will be used to develop a vaccine for Helicobacter pylorus (H. pylori), which causes more than 90 percent of duodenal ulcersand up to 80 percent of gastric ulcers.